Familial aggregation of seizure outcomes in four familial epilepsy cohorts.
familial epilepsy
genetics
meta‐analysis
remission
treatment response
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
13 May 2024
13 May 2024
Historique:
revised:
24
04
2024
received:
12
09
2023
accepted:
25
04
2024
medline:
13
5
2024
pubmed:
13
5
2024
entrez:
13
5
2024
Statut:
aheadofprint
Résumé
To assess the possible effects of genetics on seizure outcome by estimating the familial aggregation of three outcome measures: seizure remission, history of ≥4 tonic-clonic seizures, and seizure control for individuals taking antiseizure medication. We analyzed families containing multiple persons with epilepsy in four previously collected retrospective cohorts. Seizure remission was defined as being 5 and 10 years seizure-free at last observation. Total number of tonic-clonic seizures was dichotomized at <4 and ≥4 seizures. Seizure control in patients taking antiseizure medication was defined as no seizures for 1, 2, and 3 years. We used Bayesian generalized linear mixed-effects model (GLMM) to estimate the intraclass correlation coefficient (ICC) of the family-specific random effect, controlling for epilepsy type, age at epilepsy onset, and age at last data collection as fixed effects. We analyzed each cohort separately and performed meta-analysis using GLMMs. The combined cohorts included 3644 individuals with epilepsy from 1463 families. A history of ≥4 tonic-clonic seizures showed strong familial aggregation in three separate cohorts and meta-analysis (ICC .28, 95% confidence interval [CI] .21-.35, Bayes factor 8 × 10 A history of ≥4 tonic-clonic seizures aggregated strongly in families, suggesting a genetic influence, whereas seizure remission and seizure control for individuals taking antiseizure medications did not aggregate consistently in families. Different seizure outcomes may have different underlying biology and risk factors. These findings should inform the future molecular genetic studies of seizure outcomes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NINDS NIH HHS
ID : K23NS121520
Pays : United States
Organisme : NINDS NIH HHS
ID : R01NS20656
Pays : United States
Organisme : NINDS NIH HHS
ID : R01NS43472
Pays : United States
Organisme : NINDS NIH HHS
ID : U01NS053998
Pays : United States
Organisme : NINDS NIH HHS
ID : U01NS077367
Pays : United States
Informations de copyright
© 2024 International League Against Epilepsy.
Références
Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314–319.
Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30‐year longitudinal cohort study. JAMA Neurol. 2018;75(3):279–286.
Cockerell OC, Sander JWAS, Hart YM, Shorvon SD, Johnson AL. Remission of epilepsy: results from the National General Practice Study of epilepsy. Lancet. 1995;346(8968):140–144.
Sillanpää M, Schmidt D. Natural history of treated childhood‐onset epilepsy: prospective, long‐term population‐based study. Brain. 2006;129(3):617–624.
Sillanpää M, Schmidt D, Saarinen MM, Shinnar S. Remission in epilepsy: how long is enough? Epilepsia. 2017;58(5):901–906.
Berg AT, Rychlik K. The course of childhood‐onset epilepsy over the first two decades: a prospective, longitudinal study. Epilepsia. 2015;56(1):40–48.
Beghi E, Beretta S, Carone D, Zanchi C, Bianchi E, Pirovano M, et al. Prognostic patterns and predictors in epilepsy: a multicentre study (PRO‐LONG). J Neurol Neurosurg Psychiatry. 2019;90(11):1276–1285.
Löscher W, Potschka H, Sisodiya SM, Vezzani A. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020;72(3):606–638.
Gesche J, Beier CP. Drug resistance in idiopathic generalized epilepsies: evidence and concepts. Epilepsia. 2022;63(12):3007–3019.
Ellis CA, Petrovski S, Berkovic SF. Epilepsy genetics: clinical impacts and biological insights. Lancet Neurol. 2020;19(1):93–100.
Peljto AL, Barker‐Cummings C, Vasoli VM, Leibson CL, Hauser WA, Buchhalter JR, et al. Familial risk of epilepsy: a population‐based study. Brain. 2014;137(Pt 3):795–805.
Winawer MR, Rabinowitz D, Barker‐Cummings C, Scheuer ML, Pedley TA, Hauser WA, et al. Evidence for distinct genetic influences on generalized and localization‐related epilepsy. Epilepsia. 2003;44(9):1176–1182.
Winawer MR, Rabinowitz D, Pedley TA, Hauser WA, Ottman R. Genetic influences on myoclonic and absence seizures. Neurology. 2003;61(11):1576–1581.
Tobochnik S, Fahlstrom R, Shain C, Winawer MR, For the EPGP Investigators. Familial aggregation of focal seizure semiology in the epilepsy phenome/genome project. Neurology. 2017;89(1):22–28.
Ellis CA, Churilov L, Epstein MP, Xie SX, Bellows ST, Ottman R, et al. Epilepsy in families: age at onset is a familial trait, independent of syndrome. Ann Neurol. 2019;86(1):91–98.
Weisenberg JLZ, Fitzgerald RT, Constantino JN, Winawer MR, Thio LL, EPGP Investigators. Familial aggregation of status epilepticus in generalized and focal epilepsies. Neurology. 2020;95(15):e2140–e2149.
Winawer MR, Shih J, Beck ES, Hunter JE, Epstein MP, the EPGP Investigators. Genetic effects on sleep/wake variation of seizures. Epilepsia. 2016;57(4):557–565.
Pedley TA, Hirano M. Is refractory epilepsy due to genetically determined resistance to antiepileptic drugs? N Engl J Med. 2003;348(15):1480–1482.
Johnson MR, Milne RL, Torn‐Broers Y, Hopper JL, Scheffer IE, Berkovic SF. A twin study of genetic influences on epilepsy outcome. Twin Res. 2003;6(2):140–146.
Annegers JF, Hauser WA, Anderson VE, Kurland LT. The risks of seizure disorders among relatives of patients with childhood onset epilepsy. Neurology. 1982;32(2):174–179.
Annegers JF, Rocca WA, Hauser WA. Causes of epilepsy: contributions of the Rochester epidemiology project. Mayo Clin Proc. 1996;71(6):570–575.
Ottman R, Susser M. Data collection strategies in genetic epidemiology: the epilepsy family study of Columbia University. J Clin Epidemiol. 1992;45(7):721–727.
Ottman R, Berenson K, Barker‐Cummings C. Recruitment of families for genetic studies of epilepsy. Epilepsia. 2005;46(2):290–297.
Ottman R, Hauser WA, Stallone L. Semistructured interview for seizure classification: agreement with physicians' diagnoses. Epilepsia. 1990;31(1):110–115.
Ottman R, Lee JH, Hauser WA, Hong S, Hesdorffer D, Schupf N, et al. Reliability of seizure classification using a semistructured interview. Neurology. 1993;43(12):2526–2530.
Ottman R, Hauser WA, Susser M. Validity of family history data on seizure disorders. Epilepsia. 1993;34(3):469–475.
Ottman R, Barker‐Cummings C, Leibson CL, Vasoli VM, Hauser WA, Buchhalter JR. Accuracy of family history information on epilepsy and other seizure disorders. Neurology. 2011;76(4):390–396.
EPGP Collaborative, Abou‐Khalil B, Alldredge B, et al. The epilepsy phenome/genome project. Clin Trials. 2013;10(4):568–586.
Epi4K Consortium. Epi4K: gene discovery in 4,000 genomes. Epilepsia. 2012;53(8):1457–1467.
Epi4K Consortium. Phenotypic analysis of 303 multiplex families with common epilepsies. Brain. 2017;140(8):2144–2156.
Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia. 1979;20(6):729–737.
Berg AT, Rychlik K, Levy SR, Testa FM. Complete remission of childhood‐onset epilepsy: stability and prediction over two decades. Brain. 2014;137(12):3213–3222.
Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475–482.
Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. How long for epilepsy remission in the ILAE definition? Epilepsia. 2017;58(8):1486–1487.
Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies: definition of drug resistant epilepsy. Epilepsia. 2009;51(6):1069–1077.
Nielsen NM, Smink WAC, Fox J‐P. Small and negative correlations among clustered observations: limitations of the linear mixed effects model. Behav Ther. 2021;48(1):51–77.
Kenny DA, Mannetti L, Pierro A, Livi S, Kashy DA. The statistical analysis of data from small groups. J Pers Soc Psychol. 2002;83(1):126–137.
Wagenmakers E‐J, Marsman M, Jamil T, Ly A, Verhagen J, Love J, et al. Bayesian inference for psychology. Part I: theoretical advantages and practical ramifications. Psychon Bull Rev. 2018;25(1):35–57.
Kruschke JK, Liddell TM. The Bayesian new statistics: hypothesis testing, estimation, meta‐analysis, and power analysis from a Bayesian perspective. Psychon Bull Rev. 2018;25(1):178–206.
Keysers C, Gazzola V, Wagenmakers E‐J. Using Bayes factor hypothesis testing in neuroscience to establish evidence of absence. Nat Neurosci. 2020;23(7):788–799.
Bürkner P‐C. Brms: an R package for Bayesian multilevel models using Stan. J Stat Softw. 2017;80:1–28.
Gelman A. Prior distributions for variance parameters in hierarchical models (comment on article by Browne and Draper). Bayesian Anal. 2006;1(3):515–534.
Aguilar JE, Bürkner P‐C. Intuitive joint priors for Bayesian linear multilevel models: the R2D2M2 prior. Electron J Stat. 2023;17(1):1711–1767.
Polson NG, Scott JG. On the half‐Cauchy prior for a global scale parameter. Bayesian Anal. 2012;7(4):887–902.
Wu S, Crespi CM, Wong WK. Comparison of methods for estimating the intraclass correlation coefficient for binary responses in cancer prevention cluster randomized trials. Contemp Clin Trials. 2012;33(5):869–880.
Leclercq K, Kaminski RM. Genetic background of mice strongly influences treatment resistance in the 6 Hz seizure model. Epilepsia. 2015;56(2):310–318.
Berg AT, Lin J, Ebrahimi N, Testa FM, Levy SR, Shinnar S. Modeling remission and relapse in pediatric epilepsy: application of a Markov process. Epilepsy Res. 2004;60(1):31–40.
Bonnett LJ, Powell GA, Tudur Smith C, Marson AG. Breakthrough seizures—further analysis of the standard versus new antiepileptic drugs (SANAD) study. PLoS One. 2017;12(12):e0190035.
Chen H, Amdur R, Pauldurai J, Koubeissi M. Seizure recurrence after prolonged seizure control: patterns and risk factors. Epilepsy Behav. 2021;124:108330.
Schiller Y. Seizure relapse and development of drug resistance following long‐term seizure remission. Arch Neurol. 2009;66(10):7.
Callaghan B, Schlesinger M, Rodemer W, Pollard J, Hesdorffer D, Allen Hauser W, et al. Remission and relapse in a drug‐resistant epilepsy population followed prospectively: drug‐resistant epilepsy population. Epilepsia. 2011;52(3):619–626.
Wolking S, Campbell C, Stapleton C, McCormack M, Delanty N, Depondt C, et al. Role of common genetic variants for drug‐resistance to specific anti‐seizure medications. Front Pharmacol. 2021;12:688386.
Wolking S, Moreau C, McCormack M, Krause R, Krenn M, EpiPGx Consortium, et al. Assessing the role of rare genetic variants in drug‐resistant, non‐lesional focal epilepsy. Ann Clin Transl Neurol. 2021;8(7):1376–1387.
Wolking S, Moreau C, Nies AT, Schaeffeler E, McCormack M, Auce P, et al. Testing association of rare genetic variants with resistance to three common antiseizure medications. Epilepsia. 2020;61(4):657–666.